Coronavirus https://www.bioworld.com/rss en-us Free access to BioWorld coronavirus articles The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added five critical tables, which are continuously updated: Biopharma vaccines and therapeutics in development Diagnostics with U.S. FDA emergency use authorization Clinical trials of biopharma products affected by COVID-19 Therapeutics and vaccines Med-tech diagnostics BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added five critical tables, which are continuously updated:

Biopharma vaccines and therapeutics in development
Diagnostics with U.S. FDA emergency use authorization
Clinical trials of biopharma products affected by COVID-19

Therapeutics and vaccines
Med-tech diagnostics

]]> http://www.bioworld.com/articles/694975 Fri, 12 Jun 2026 09:30:00 -0400 https://www.bioworld.com/articles/694975-free-access-to-bioworld-coronavirus-articles FDA clears Shionogi’s Xocova as first COVID-19 prevention pill The U.S. FDA approved Shionogi & Co. Ltd.’s Xocova (ensitrelvir) as the first oral post-exposure prophylactic option in the U.S. to prevent COVID-19, with the decision coming ahead of a PDUFA target date of June 16. http://www.bioworld.com/articles/731531 Tue, 02 Jun 2026 08:00:00 -0400 https://www.bioworld.com/articles/731531-fda-clears-shionogis-xocova-as-first-covid-19-prevention-pill Xocova blister pack Credit: Shionogi & Co. Ltd. FDA’s VRBPAC faces complex COVID-19 landscape Landing on the right COVID-19 vaccine formulation for the coming season is becoming more complicated against a backdrop of low vaccination rates, young children with little to no immunization, declining surveillance data and a new SARS-COV-2 lineage slowly emerging. http://www.bioworld.com/articles/731442 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731442-fdas-vrbpac-faces-complex-covid-19-landscape COVID-19 vaccine vials on conveyor belt New evidence links autoimmunity to long COVID symptoms Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that autoimmunity might underlie the persistent neurological symptoms seen in long COVID, researchers at Yale University and Mount Sinai now reinforce this hypothesis. SARS-CoV-2 infection appears to trigger an autoimmune mechanism that drives chronic pain, fatigue and cognitive impairment in some patients. http://www.bioworld.com/articles/731473 Thu, 28 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731473-new-evidence-links-autoimmunity-to-long-covid-symptoms Illustration of antibodies and viral infection Kennedy offers emergency immunity for use of MCM in hantavirus Acknowledging that the spread of the Andes virus and the resulting disease, hantavirus pulmonary syndrome, “constitutes a credible risk of a future public health emergency,” U.S. Health and Human Services Secretary Robert Kennedy is issuing a declaration to provide liability protection for manufacturers, distributors and providers using favipiravir as a medical countermeasure (MCM) against the virus. http://www.bioworld.com/articles/731406 Tue, 26 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731406-kennedy-offers-emergency-immunity-for-use-of-mcm-in-hantavirus FDA adcom to consider next iteration of COVID-19 vaccines What would normally be a routine meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee May 28 may be more carefully watched given the overall turmoil surrounding vaccines in the U.S. The only task before the adcom is to recommend the COVID-19 vaccine formula for the upcoming season. That conversation will include looking at the effectiveness of the four FDA-approved vaccines currently in use in the U.S. http://www.bioworld.com/articles/731405 Tue, 26 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731405-fda-adcom-to-consider-next-iteration-of-covid-19-vaccines Next-generation PLpro inhibitor for SARS-CoV-2 divulged Researchers from Sunshine Biopharma Inc. and the University of Arizona reported the discovery and preclinical characterization of MR-1-114, a noncovalent inhibitor of the SARS-CoV-2 papain-like protease (PLpro). http://www.bioworld.com/articles/731000 Mon, 11 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731000-next-generation-plpro-inhibitor-for-sars-cov-2-divulged Coronavirus punch Criminal charges filed against top Fauci aide An alleged coverup of NIH-funded gain-of-function research at China’s Wuhan Institute of Virology has led to criminal charges against a former career scientist and top aide to Tony Fauci, the head of the National Institute of Allergy and Infectious Diseases in the time of the COVID-19 pandemic. http://www.bioworld.com/articles/730789 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730789-criminal-charges-filed-against-top-fauci-aide AI opens the way to systematic risk assessment of zoonotic potential of viruses Researchers in the U.K. have developed an AI-driven method of identifying viruses in wild animals with the potential to spillover into humans. The technique makes it possible to use the genome sequences of the spike proteins by which viruses enter host cells to assess the potential to infect humans without having to isolate an individual virus and tests its infectivity in the lab. http://www.bioworld.com/articles/730553 Wed, 22 Apr 2026 11:00:00 -0400 https://www.bioworld.com/articles/730553-ai-opens-the-way-to-systematic-risk-assessment-of-zoonotic-potential-of-viruses Heart-nosed bats (Cardioderma cor) hanging from the rafters ACE2-nanobody fusion enables pan-sarbecovirus neutralization SARS-CoV-2 utilizes the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry and triggers ACE2 ectodomain shedding, which results in elevated vasoconstrictor angiotensin II (Ang-II) while depleting the protective Ang-(1-7). This effect can lead to acute respiratory distress syndrome, hypertension, acute kidney injury and organ damage. http://www.bioworld.com/articles/730330 Mon, 13 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730330-ace2-nanobody-fusion-enables-pan-sarbecovirus-neutralization Coronavirus viral membrane The illustration shows a viral membrane decorated with spike glycoproteins; highlighted in red is a potential neutralization site, which is a protein sequence that might be used as a target for vaccines to combat viruses such as MERS-CoV and other coronaviruses. Credit: David Veesler, University of Washington COVID-19 mRNA vaccine provides broad-spectrum protection Researchers from the University of Naples Federico II (Italy) and collaborating institutions reportedd the design of a next-generation mRNA vaccine that leverages a phylogenetically informed consensus receptor binding domain heterotrimers representing the major variant lineages. http://www.bioworld.com/articles/730096 Thu, 02 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730096-covid-19-mrna-vaccine-provides-broad-spectrum-protection Moderna to pay up to $2.25B to settle COVID-19 patents case In what it says could be the largest disclosed patent settlement in the pharmaceutical industry, Roivant Sciences Ltd. has reached a potential $2.25 billion settlement with Moderna Inc. over the use of its lipid nanoparticle delivery technology in the Spikevax COVID-19 vaccine. http://www.bioworld.com/articles/729387 Wed, 04 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729387-moderna-to-pay-up-to-225b-to-settle-covid-19-patents-case Spikevax vial and product packaging Credit: Moderna Inc. Moderna’s flu vaccine back in play as FDA shifts course on review A week after catching Moderna Inc. and its investors off guard with a refuse-to-file letter, the U.S. FDA has reversed course on the company’s BLA submission seeking approval of seasonal influenza vaccine mRNA-1010, now agreeing to review the application and setting an assigned PDUFA date of Aug. 5, 2026. http://www.bioworld.com/articles/729070 Wed, 18 Feb 2026 12:05:00 -0500 https://www.bioworld.com/articles/729070-modernas-flu-vaccine-back-in-play-as-fda-shifts-course-on-review FDA vaccine illustration Centre Hospitalier Regional Universitaire de Lille divulges new 3CLpro inhibitors Centre Hospitalier Regional Universitaire de Lille has patented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19). http://www.bioworld.com/articles/728215 Fri, 23 Jan 2026 08:00:00 -0500 https://www.bioworld.com/articles/728215-centre-hospitalier-regional-universitaire-de-lille-divulges-new-3clpro-inhibitors New 3CLpro inhibitors disclosed in Nxera Pharma patent Nxera Pharma UK Ltd. has divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19). http://www.bioworld.com/articles/727756 Thu, 08 Jan 2026 08:00:00 -0500 https://www.bioworld.com/articles/727756-new-3clpro-inhibitors-disclosed-in-nxera-pharma-patent Vaccines: From the toast of the town to being in the crosshairs BioWorld’s 2022 end-of-year highlights included a toast to the future – of universal vaccines. Even before SARS-CoV-2 vaccines were developed in record time and saved countless lives during the COVID-19 pandemic, vaccines were a rare bright spot in the fight against infectious diseases. Bacteria are becoming multidrug resistant far faster than new classes of antibiotics are being developed, viral spillover events and vector ranges are increasing, and climate change is helping bacteria and fungi alike breach human thermal protections against infections. http://www.bioworld.com/articles/727420 Tue, 23 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/727420-vaccines-from-the-toast-of-the-town-to-being-in-the-crosshairs COVID-19 vial in a line of toppled dominoes Research unpicks molecular mechanism of vaccine-induced cardiac inflammation The cardiomyositis that is a rare adverse effect of mRNA-based COVID vaccines is due to immune cell activity as a result of increased levels of the chemokines CXCL10 and interferon-γ (IFN-γ). Blocking CXCL10 and IFN-γ could prevent muscle cell damage in cell culture, and cardiomyositis in animal models. The findings, reported in the Dec. 10, 2025, issue of Science Translational Medicine, suggest a way of mitigating the risk of cardiomyositis. Science Translational Medicine, suggest a way of mitigating the risk of cardiomyositis.]]> http://www.bioworld.com/articles/727106 Fri, 12 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/727106-research-unpicks-molecular-mechanism-of-vaccine-induced-cardiac-inflammation Person with chest pain after receiving a COVID-19 vaccine Petition claims FDA oops! means COVID-19 vaccines misbranded Restricting the recommended use of COVID-19 vaccines in the U.S. wasn’t enough. Now the Children’s Health Defense (CHD) is trying to get the FDA to revoke the BLAs for all versions of the Moderna Inc. and Pfizer Inc.-Biontech SE COVID-19 vaccines. http://www.bioworld.com/articles/727145 Thu, 11 Dec 2025 12:00:00 -0500 https://www.bioworld.com/articles/727145-petition-claims-fda-oops-means-covid-19-vaccines-misbranded COVID-19 vaccine vials on conveyor belt Aligos and KU Leuven divulge new antivirals Aligos Therapeutics Inc. and Katholieke Universiteit Leuven (KU Leuken) have synthesized antiviral compounds reported to be useful for the treatment of coronavirus acute respiratory syndrome, norovirus and picornavirus infections. http://www.bioworld.com/articles/725937 Mon, 10 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725937-aligos-and-ku-leuven-divulge-new-antivirals Ena Respiratory raises AU$34M series B to fund phase II trial Ena Respiratory Pty Ltd. raised an AU$34 million (US$22.4 million) series B round to advance INNA-051, its nasal spray for symptomatic viral respiratory infections, to phase II trials. New investors in the Melbourne-headquartered company include the Gates Foundation and Flu Lab. Existing investors Brandon Capital, Uniseed and Stoic Venture Capital also participated in the round. http://www.bioworld.com/articles/725685 Tue, 28 Oct 2025 11:00:00 -0400 https://www.bioworld.com/articles/725685-ena-respiratory-raises-au34m-series-b-to-fund-phase-ii-trial Ena Respiratory's INNA-051 Ena Respiratory's INNA-051 is being developed as a convenient, once-a-week nasal dry powder product to reduce the impact of viral respiratory infections and prevent severe complications in at-risk populations. Credit: Ena Respiratory Pty Ltd. Ena Respiratory raises AU$34M series B to fund phase II trial Ena Respiratory Pty Ltd. raised an AU$34 million (US$22.4 million) series B round to advance INNA-051, its nasal spray for symptomatic viral respiratory infections, to phase II trials. New investors in the Melbourne-headquartered company include the Gates Foundation and Flu Lab. Existing investors Brandon Capital, Uniseed and Stoic Venture Capital also participated in the round. http://www.bioworld.com/articles/725389 Thu, 23 Oct 2025 11:00:00 -0400 https://www.bioworld.com/articles/725389-ena-respiratory-raises-au34m-series-b-to-fund-phase-ii-trial Ena Respiratory's INNA-051 Ena Respiratory's INNA-051 is being developed as a convenient, once-a-week nasal dry powder product to reduce the impact of viral respiratory infections and prevent severe complications in at-risk populations. Credit: Ena Respiratory Pty Ltd. Atomic layer deposition enhances antibody responses to a mosaic sarbecovirus vaccine Atomic layer deposition (ALD) is a recently proposed vaccine technology. http://www.bioworld.com/articles/724962 Wed, 08 Oct 2025 09:00:00 -0400 https://www.bioworld.com/articles/724962-atomic-layer-deposition-enhances-antibody-responses-to-a-mosaic-sarbecovirus-vaccine Latest ACIP recommendations added to CDC vaccine schedules Even though the U.S. CDC is operating on a skeleton crew due to the partial government shutdown, it is updating its immunization schedules to adopt the COVID-19 and chickenpox vaccine recommendations the Advisory Committee on Immunization Practices (ACIP) made at its September meeting. http://www.bioworld.com/articles/725023 Tue, 07 Oct 2025 11:00:00 -0400 https://www.bioworld.com/articles/725023-latest-acip-recommendations-added-to-cdc-vaccine-schedules Vaccine vial and syringe Latest ACIP recommendations added to CDC vaccine schedules Even though the U.S. CDC is operating on a skeleton crew due to the partial government shutdown, it is updating its immunization schedules to adopt the COVID-19 and chickenpox vaccine recommendations the Advisory Committee on Immunization Practices (ACIP) made at its September meeting. http://www.bioworld.com/articles/724841 Mon, 06 Oct 2025 11:00:00 -0400 https://www.bioworld.com/articles/724841-latest-acip-recommendations-added-to-cdc-vaccine-schedules Vaccine vial and syringe So far, ACIP vaccine recommendations in line with the world While the discussions and votes at the past two meetings of the U.S. CDC Advisory Committee for Immunization Practices (ACIP) have generated a lot of controversy and resulted in some states and medical groups issuing their own vaccine schedules, the truth is that the newly reconstituted committee’s recommendations to date are still in line with, or more generous in some instances than, global norms. http://www.bioworld.com/articles/724715 Thu, 02 Oct 2025 11:00:00 -0400 https://www.bioworld.com/articles/724715-so-far-acip-vaccine-recommendations-in-line-with-the-world Global vaccine illustration In the clinic for Sept. 24, 2025 Clinical updates, including data readouts and publications: Aphaia, Atai, Beckley Psytech, BMS, Moderna, Neurocrine, Sensory Cloud. http://www.bioworld.com/articles/724405 Wed, 24 Sep 2025 11:00:00 -0400 https://www.bioworld.com/articles/724405-in-the-clinic-for-sept-24-2025 GC Biopharma files Korean IND for COVID-19 mRNA vaccine GC Biopharma Corp. has filed an IND application with the South Korean Ministry of Food and Drug Safety (MFDS) for a phase I trial of GC-4006A, an mRNA vaccine candidate for COVID-19. http://www.bioworld.com/articles/724434 Tue, 23 Sep 2025 09:00:00 -0400 https://www.bioworld.com/articles/724434-gc-biopharma-files-korean-ind-for-covid-19-mrna-vaccine Gloved hands holding mRNA vaccine vial Decide on COVID-19 shot at your own peril: ACIP The second day’s meeting of the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) took up guidelines related to COVID-19 vaccines, of which an outspoken skeptic is Health and Human Services Secretary Robert Kennedy – who in June fired all 17 members of ACIP and replaced them with names more to his liking. http://www.bioworld.com/articles/724527 Mon, 22 Sep 2025 11:00:00 -0400 https://www.bioworld.com/articles/724527-decide-on-covid-19-shot-at-your-own-peril-acip COVID-19 vial, syringe and vaccine card Decide on COVID-19 shot at your own peril: ACIP The second day’s meeting of the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) took up guidelines related to COVID-19 vaccines, of which an outspoken skeptic is Health and Human Services Secretary Robert Kennedy – who in June fired all 17 members of ACIP and replaced them with names more to his liking. http://www.bioworld.com/articles/724311 Fri, 19 Sep 2025 11:00:00 -0400 https://www.bioworld.com/articles/724311-decide-on-covid-19-shot-at-your-own-peril-acip COVID-19 vial, syringe and vaccine card Cancer vaccines face collateral damage of mRNA funding cuts When Robert Kennedy Jr. announced the cancellation of 22 projects related to mRNA vaccines and the end of new investments in that technology, the U.S. Secretary of Health only mentioned their use against respiratory viruses, without referring to other applications. The vaccines whose safety and effectiveness Kennedy is questioning are based on the same molecular principles as cancer vaccines under development. “Continued investment in mRNA technology is essential to fully realize its potential in oncology and ensure that promising strategies like neoantigen-based vaccines reach clinical application.” Kazuhiro Kakimi, professor at the Department of Immunology at Kindai University Faculty of Medicine, told BioWorld. BioWorld.]]> http://www.bioworld.com/articles/724274 Wed, 17 Sep 2025 09:00:00 -0400 https://www.bioworld.com/articles/724274-cancer-vaccines-face-collateral-damage-of-mrna-funding-cuts Syringe in spotlight